Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia

Hellard ME, Jenkinson R, Higgs P, Stoove MA, Sacks-Davis R, Gold J, et al. Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia. Med J Aust. 2012;196(10):638-641.

Publication Type:

Journal Article

Authors:

Hellard, M.E.; Jenkinson, R.; Higgs, P.; Stoove, M.A.; Sacks-Davis, R.; Gold, J.; Hickman, M.; Vickerman, P.; N K Martin

Source:

Med J Aust, Volume 196, Issue 10, p.638-641 (2012)

Keywords:

Antiviral Agents, Australia, chronic HCV, complications, Drug Therapy,Combination, Drug Users, epidemiology, Evaluation Studies, HCV, Health, hepatitis, Hepatitis C, hepatitis C virus, Hepatitis C,Chronic, Humans, Infection, Interferon-alpha, interventions, Models,Biological, Mortality, peginterferon, Polyethylene Glycols, Prevalence, prevention & control, Proteins, Recombinant Proteins, Ribavirin, Substance Abuse,Intravenous, therapeutic use, transmission, treatment, Victoria

Cited On:

When and in Whom to Initiate HCV Therapy

External Third-party Web Link:

http://www.ncbi.nlm.nih.gov/pubmed/22676879

Export Citation:

RIS Format

Top